Antioxidant and antiproliferative activities of six Malaysian medicinal plants and mechanism of action through microrna in thyroid cell lines by Ismail, Aziana
ANTIOXIDANT AND ANTIPROLIFERATIVE 
ACTIVITIES OF SIX MALAYSIAN MEDICINAL 
PLANTS AND MECHANISM OF ACTION 






















UNIVERSITI SAINS MALAYSIA 
 
2019 
ANTIOXIDANT AND ANTIPROLIFERATIVE 
ACTIVITIES OF SIX MALAYSIAN MEDICINAL 
PLANTS AND MECHANISM OF ACTION 













Thesis submitted in fulfillment of the requirements 
for the degree of 










I would like to express my sincerest gratitude and appreciation to my advisors, 
Associate Professor Dr. Khoo Boon Yin and Associate Professor Dr. Maizan 
Mohamed for the opportunity to have been their student for the past five years and for 
their guidance throughout the lab work and thesis writing. To my advisors, Professor 
Shaharum Shamsuddin and Professor Prabha Balaram, thank you for your ideas and 
comments over the course of my studies. Their dedication to research was inspiring.  
 
To all lab mates past and present, thank you for the laughs and the memories. I would 
also like to thank the former and current members of INFORMM Kubang Kerian for 
the support and experience. I would also like to acknowledge other people who have 
directly and indirectly help me towards the completion of my study.  
 
Most importantly, I would like to thank my mother, Wan Mas Wan Senik for 
supporting me, emotionally in completing my study. To my beloved husband, Wan 
Mohd Izuadi Wan Mahmud, thank you for believing in me and for being patient with 
me throughout this journey that made my accomplishments worth celebrating. I would 
like to dedicate this thesis to my daughter and son, Wan Nur Iris Wan Mohd Izuadi 
and Wan Mohamad Irsyad Wan Mohd Izuadi for you are the reason for me to keep on 
improving myself to become a better person and a better mother to you. Lastly, I would 
also like to thank the USM fellowship for providing the funding that has made this 





TABLE OF CONTENT 
 
ACKNOWLEDGMENT .............................................................................................. ii 
TABLE OF CONTENT .............................................................................................. iii 
LIST OF TABLES ....................................................................................................... x 
LIST OF FIGURES.................................................................................................... xii 
LIST OF EQUATIONS ........................................................................................... xvii 
LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS ........................... xviii 
ABSTRAK  ............................................................................................................. xxi 
ABSTRACT  ........................................................................................................... xxiii 
CHAPTER 1: INTRODUCTION ................................................................................ 1 
1.1 Rationale of the study ......................................................................................... 1 
1.2 Aim and scope of the study ................................................................................ 3 
1.3 Overview of the study ......................................................................................... 4 
CHAPTER 2: LITERATURE REVIEW ..................................................................... 7 
2.1 Cancer ................................................................................................................. 7 
2.1.1 Thyroid cancers ....................................................................................... 9 
2.2 Cancer biology .................................................................................................. 13 
2.3 Oxidative stress and cancer development ......................................................... 16 
2.4 Genetic mutations in cancer cells ..................................................................... 19 
2.5 MicroRNAs deregulation in cancer .................................................................. 25 
2.6 MicroRNA biogenesis ...................................................................................... 26 
2.7 MicroRNAs and thyroid cancer ........................................................................ 28 
2.8 The need for new anti-cancer drugs.................................................................. 29 
2.9 Natural products in traditional medicine .......................................................... 31 
 
iv 
2.10 Natural products in modern drug discovery ..................................................... 33 
2.11 Antioxidants as anti-cancer agents ................................................................... 35 
2.12 Phytochemicals ................................................................................................. 36 
2.12.1 Polyphenols ........................................................................................... 39 
2.12.2 Alkaloids ............................................................................................... 41 
2.12.3 Terpenoids ............................................................................................ 42 
2.13 Plants with promising anti-cancer property ...................................................... 43 
2.13.1 Angelica keiskei Ito ............................................................................... 45 
2.13.2 Annona muricata L. .............................................................................. 46 
2.13.3 Chromolaena odorata (L.) R. M. King & H. Rob ................................ 47 
2.13.4 Clinacanthus nutans (Burm. f.) Lindau ................................................ 49 
2.13.5 Euphorbia hirta L. ................................................................................ 50 
2.13.6 Leea indica (Burm. f.) Merr. ................................................................. 51 
CHAPTER 3: MATERIALS AND METHODS........................................................ 53 
3.1 Materials ........................................................................................................... 53 
3.1.1 Chemicals .............................................................................................. 53 
3.1.2 Solutions and buffers ............................................................................ 54 
3.1.3 Media preparation ................................................................................. 54 
3.1.4 Kits ........................................................................................................ 54 
3.1.5 Plasticware and consumables ................................................................ 55 
3.1.6 Equipment ............................................................................................. 55 
3.1.7 Primer and probes ................................................................................. 56 
3.1.8 Plant materials ....................................................................................... 57 
3.1.9 Human cell lines ................................................................................... 57 
3.2 Methods ............................................................................................................ 58 
 
v 
3.2.1 Plant preparation ................................................................................... 58 
3.2.1(a) Identification of plants ......................................................... 58 
3.2.1(b) Preparation of plant material ................................................ 58 
3.2.1(c) Preparation of crude plant extract ........................................ 58 
3.2.1(d)   Preparation of stock and working concentration of crude 
plant extract .......................................................................... 61 
3.2.2 Determination of total phenolic content ............................................... 61 
3.2.3 Determination of total flavonoid content .............................................. 64 
3.2.4 Determination of free radical (DPPH) scavenging activity .................. 67 
3.2.5 Cell culture ............................................................................................ 70 
3.2.5(a) Resuscitation of frozen cell lines.......................................... 70 
3.2.5(b) Sub-culturing of adherent cell lines...................................... 70 
3.2.5(c) Quantification of cell number and cell viability ................... 73 
3.2.5(d) Cryopreservation and storage of cells .................................. 74 
3.2.5 (e) Cell-growth curve ................................................................. 75 
3.2.6 Cell viability assay (MTT assay) .......................................................... 76 
3.2.6(a) Preparation of MTT reagent ................................................. 77 
3.2.6(b) Determination of cell viability of thyroid cells treated with 
crude plant extracts using MTT assay .................................. 77 
3.2.6(c) Determination of percentage of viable cells and 50% 
inhibitory concentration (IC50) ............................................. 78 
3.2.7 Cell morphological analysis .................................................................. 78 
3.2.7(a) Acridine orange (AO)/ ethidium bromide (EB) staining 
assay ..................................................................................... 80 
3.2.8 Cell cycle analysis by DNA content ..................................................... 80 
 
vi 
3.2.9 Apoptotic analysis with Annexin V-FITC/ propidium iodide (PI) 
double-staining assay ............................................................................ 81 
3.2.10 Apoptotic analysis with Terminal Deoxynucleotidyltransferase-
mediated dUTP Nick End Labeling (TUNEL) staining assay .............. 82 
3.2.11 Quantification of mRNA level of apoptosis-related genes through 
quantitative real-time PCR (qPCR) ...................................................... 82 
3.2.11(a) RNA extraction and first-strand cDNA synthesis ................ 82 
3.2.11(b) Optimization of primer annealing temperature for 
quantitative real-time PCR ................................................... 84 
3.2.11(c) Quantitative real-time PCR (qPCR) assay ........................... 85 
3.2.12 Quantification of candidate microRNAs level through quantitative 
real-time PCR (qPCR) .......................................................................... 85 
3.2.12(a) RNA extraction and first-strand cDNA synthesis ................ 85 
3.2.12(b) Quantitative real-time PCR (qPCR) assay ........................... 86 
3.2.13 Statistical analyses ................................................................................ 87 
CHAPTER 4 : RESULTS .......................................................................................... 88 
4.1 Evaluation of the antioxidant activity of the plant extracts .............................. 88 
4.1.1 Percentage yield of plant extraction ...................................................... 88 
4.1.2 Total phenolic content of crude plant extracts ...................................... 89 
4.1.3 Total flavonoid content of crude plant extracts .................................... 93 
4.1.4 Free radical scavenging activity of crude plant extracts ....................... 97 
4.1.5 Correlations of antioxidant activity, total phenolic content and total 
flavonoid content among crude plant extracts .................................... 100 
4.2 Evaluation of anti-proliferative activity of crude plant extracts on thyroid 
cell lines .......................................................................................................... 102 
 
vii 
4.2.1 Growth characteristics of thyroid cells ............................................... 102 
4.2.2 Anti-proliferative effect of aqueous plant extracts on Nthy-ori 3-1  .. 104 
4.2.3 Anti-proliferative effect of methanolic plant extracts on Nthy-ori 
3-1  ...................................................................................................... 108 
4.2.4 Anti-proliferative effect of aqueous plant extracts on FTC-133  ........ 111 
4.2.5 Anti-proliferative effect of methanolic plant extracts on FTC-133  ... 114 
4.2.6 Anti-proliferative effect of aqueous plant extracts on Hth-74 cells .... 117 
4.2.7 Anti-proliferative effect of methanolic plant extracts on Hth-74  ...... 120 
4.2.8 Summary of anti-proliferative effects of A. muricata and C. 
odorata methanolic extracts ................................................................ 123 
4.3 Morphological observations of follicular thyroid cells treated with A. 
muricata methanolic extract ........................................................................... 125 
4.4 Cell cycle analysis by DNA content in thyroid cells treated with A. 
muricata methanolic extract ........................................................................... 132 
4.5  Detection of apoptosis in FTC-133 cells treated with A. muricata 
methanolic extract using Annexin V-FITC/propidium iodide staining .......... 136 
4.6 Quantification of DNA fragmentation in FTC-133 cells treated with A. 
muricata methanolic extract ........................................................................... 139 
4.7 Modulation of apoptosis-related gene expression induced by A. muricata 
methanolic extract in FTC-133 cells............................................................... 141 
4.8 Identification of dysregulated microRNA expression and their potential 
roles in the anti-proliferative effect of A. muricata methanolic extract in 
FTC-133 cells. ................................................................................................ 143 
4.8.1 The microRNA expression levels of miR-192, miR-197, miR-328 
and miR-346 in Nthy-ori 3-1 cells and FTC-133 cells ....................... 143 
 
viii 
4.8.2 The microRNA expression levels of miR-192, miR-197, miR-328 
and miR-346 in FTC-133 cells treated with A. muricata methanolic 
extract .................................................................................................. 145 
4.8.3 Predictions of the target genes of miR-192, miR-197, miR-328 and 
miR-346 .............................................................................................. 147 
4.8.4 mRNA expression levels of candidate microRNAs target genes in 
FTC-133 cells treated with A. muricata methanolic extract ............... 148 
4.8.4(a) The mRNA expression level of target genes for miR-192 . 148 
4.8.4(b) The mRNA expression level of target genes for miR-197 . 150 
4.8.4(c) The mRNA expression level of target genes for miR-328 . 150 
4.8.4(d) The mRNA expression level of target genes for miR-346 . 153 
CHAPTER 5 : DISCUSSION .................................................................................. 155 
5.1 Selection of extraction method and solvents for extraction of bioactive 
compounds from plants. ................................................................................. 156 
5.2  Antioxidant activity of the crude plant extracts .............................................. 158 
5.2.1  Total phenolic and total flavonoid contents in the crude plant 
extract .................................................................................................. 159 
5.2.2 Free radical scavenging activities in the crude plant extracts. ............ 161 
5.2.3 Correlation analysis on total phenolic, total flavonoid and DPPH 
scavenging activity variables. ............................................................. 163 
5.3 Anti-proliferative effect of crude plant extracts on thyroid cell lines. ........... 163 
5.3.1  Growth characteristics of thyroid cell lines ........................................ 165 
5.3.2 Anti-proliferative effect of aqueous and methanolic extracts on 
thyroid cell lines. ................................................................................. 166 
 
ix 
5.4 Morphological changes of follicular thyroid cancer cell lines, FTC-133 
treated with A. muricata methanolic extract. .................................................. 170 
5.5 Induction of cell cycle arrest by A. muricata methanolic extract in FTC-
133 .................................................................................................................. 171 
5.6 Induction of apoptosis by A. muricata methanolic extract in FTC-133 cell .. 172 
5.6.1 Detection of apoptosis by flow cytometric analysis using annexin 
V-FITC/PI assay. ................................................................................ 174 
5.6.2 Detection of apoptosis by TUNEL assay. ........................................... 176 
5.6.3 Gene expression analysis of apoptosis-related genes in FTC-133 
cells treated with A. muricata methanolic extract. .............................. 177 
5.7 Analysis of microRNAs and their target genes associated with thyroid 
cancer development. ....................................................................................... 180 
5.7.1 Expression analysis of four aberrantly expressed microRNAs in 
thyroid cell lines. ................................................................................. 183 
5.7.2 Expression analysis of computationally predicted microRNA target 
genes ................................................................................................... 186 
5.8  Cancer prevention and the sustainable development goals ............................ 187 
CHAPTER 6 : CONCLUSION AND FUTURE RECOMMENDATIONS ............ 189 
REFERENCES ......................................................................................................... 194 





LIST OF TABLES 
Page 
Table 2.1 Types of thyroid cancer and their profiles. ........................................... 13 
Table 2.2 List of plants used in the present study, their local names, 
characteristics and medicinal use in traditional medicine. ................... 44 
Table 3.1 List of common chemical reagents used in the present study and 
their respective manufacturers. ............................................................. 53 
Table 3.2 List of solution and buffer used in the present study and the steps 
for preparation. ..................................................................................... 54 
Table 3.3 List of media used in the present study and the steps for 
preparation. ........................................................................................... 54 
Table 3.4 List of kits used in the present study and their respective 
manufacturers. ...................................................................................... 54 
Table 3.5 List of consumables used in the present study and their respective 
manufacturers. ...................................................................................... 55 
Table 3.6 List of equipment used in the study and their respective 
manufacturers. ...................................................................................... 55 
Table 3.7 List of primers used in the present study for quantitative real-time 
RT-PCR. ............................................................................................... 56 
Table 3.8 List of thyroid cell lines used in the present study, their 
characteristics and media used for growth of each cell line. ................ 57 
Table 3.9 List of voucher specimen for each plant as deposited in the 
Herbarium Unit, School of Biological Sciences, Universiti Sains 
Malaysia. .............................................................................................. 58 
 
xi 
Table 4.1 The percentage yield of all crude plant extracts in two solvents, 
methanol and water. Data are expressed as mean ± SD of triplicate 
experiments. ......................................................................................... 89 
Table 4.2 Absorbance of the standard compound, gallic acid (λmax = 750 
nm) at the respective concentration. ..................................................... 90 
Table 4.3  Absorbance of the standard compound, quercetin (λmax = 415 nm) 
at the respective concentration. ............................................................ 93 
Table 4.4  Percentage inhibition of DPPH by the standard, gallic acid, and 
crude plant extracts at different concentrations and their respective 
DPPH IC50 values. ................................................................................ 98 
Table 4.5  Pearson’s correlation coefficients between total phenolic, total 
flavonoid and DPPH IC50 variables.................................................... 100 
Table 4.6 List of predicted target genes for miR-192, miR-197, miR-328 and 
miR-346 as predicted in PicTar, TargetScan and miRBase. .............. 148 
 
xii 
LIST OF FIGURES 
Page 
Figure 1.1 Flow chart of the study.. ......................................................................... 6 
Figure 2.1 Thyroid Cancer. .................................................................................... 10 
Figure 2.2 Multistage process of cancer development. ......................................... 15 
Figure 2.3 Role of superoxide dismutase in inactivation of the superoxide ion. 
Superoxide dismutase (SOD) catalyzes the dismutation of the 
superoxide ion (O2 −) into oxygen (O2) and hydrogen peroxide 
(H2O2). .................................................................................................. 18 
Figure 2.4 Schematic representation of the intrinsic and extrinsic apoptosis 
pathways. .............................................................................................. 23 
Figure 2.5 Schematic representation of microRNA (microRNA) biogenesis. ...... 27 
Figure 2.6 Classification of several important dietary phytochemicals................. 38 
Figure 2.7 Chemical structure of several important phytochemicals 
commonly used for medicinal purposes. .............................................. 40 
Figure 3.1 Schematic diagram of a generic rotary evaporator with the essential 
parts shown. .......................................................................................... 60 
Figure 3.2 Schematic diagram of workflow for determination of total phenolic 
content using Folin-Ciocalteu’s method............................................... 63 
Figure 3.3 Schematic diagram of workflow for determination of total 
flavonoid content using Aluminum chloride method. .......................... 66 
Figure 3.4 Schematic diagram of workflow for determination of DPPH free 
radical scavenging activity ................................................................... 69 
Figure 3.5 Typical growth pattern of cultured cells. .............................................. 72 
Figure 3.6 Schematic diagram of MTT assay in 96-well cell culture plate ........... 79 
 
xiii 
Figure 4.1 Standard curve of gallic acid for determination of total phenolic 
content in crude plant extracts .............................................................. 90 
Figure 4.2 Total phenolic content of (a) aqueous and (b) methanolic extracts 
of plants expressed as mg GAE/g dw. .................................................. 92 
Figure 4.3 Standard curve of quercetin for determination of total flavonoid 
content in crude plant extracts. ............................................................. 94 
Figure 4.4  Total flavonoid content of (a) aqueous and (b) methanolic extracts 
of medicinal plants (mg QE/g dw). ...................................................... 96 
Figure 4.5  Percentage of scavenging activity of DPPH free radicals by (a) 
aqueous and (b) methanolic crude extracts at various 
concentrations. ...................................................................................... 99 
Figure 4.6  Linear correlation for DPPH radical scavenging vs. (a) total 
phenolic content (Pearson’s correlation coefficient, r = -0.690; p-
value > 0.05) and (b) total flavonoid content of the extracts 
(Pearson’s correlation coefficient, r = -0.708; p-value < 0.05); n=8.
 ............................................................................................................ 101 
Figure 4.7 Cellular growth curves for Nthy-ori 3-1, FTC-133 and Hth-74 cell 
lines. ................................................................................................... 103 
Figure 4.8 Percentage of Nthy-ori 3-1 cell viability when treated with aqueous 
crude extracts and cisplatin at various concentrations between 0 – 
250 µg/mL for (a) 24 hours and (b) 72 hours. .................................... 106 
Figure 4.9 Percentage of Nthy-ori 3-1 cell viability when treated with 
methanolic crude extracts and cisplatin at various concentrations 
between 0 – 250 µg/mL for (a) 24 hours and (b) 72 hours. ............... 109 
 
xiv 
Figure 4.10 Percentage of FTC-133 cell viability when treated with aqueous 
crude extracts and cisplatin at various concentrations between 0 – 
250 µg/mL for (a) 24 hours and (b) 72 hours. .................................... 112 
Figure 4.11 Percentage of FTC-133 cell viability when treated with methanolic 
crude extracts and cisplatin at various concentrations between 0 – 
250 µg/mL for (a) 24 hours and (b) 72 hours. .................................... 115 
Figure 4.12 Percentage of Hth-74 cell viability when treated with aqueous 
crude extracts and cisplatin at various concentrations between 0 – 
250 µg/mL for (a) 24 hours and (b) 72 hours. .................................... 118 
Figure 4.13 Percentage of Hth-74 cell viability when treated with methanolic 
crude extracts and cisplatin at various concentrations between 0 – 
250 µg/mL for (a) 24 hours and (b) 72 hours. .................................... 121 
Figure 4.14 Percentage of cell viability of Nthy-ori 3-1, FTC-133 and Hth-74 
cells after 72 hours of treatment and corresponding IC50 graph 
when the cells were treated with the methanolic extracts of (a-b) A. 
muricata and (c-d) C. odorata at various concentrations between 0 
– 250 µg/mL.. ..................................................................................... 124 
Figure 4.15 Morphological alterations of FTC-133 cells following exposure to 
A. muricata methanolic extract. ......................................................... 126 
Figure 4.16 Fluorescence microscopic images of cells double-stained with 
AO/EB after 24 hours and 72 hours of treatments. ............................ 128 
Figure 4.17 Quantification of cell death in FTC-133 cells induced by A. 
muricata methanolic extract. .............................................................. 131 
Figure 4.18 Flow cytometric analysis of the cell distributions in FTC-133 cells 
treated with methanolic extract of A. muricata on FTC-133. ............ 133 
 
xv 
Figure 4.19 Effects of A. muricata methanolic extract on the cell cycle 
progression of FTC-133 cells. ............................................................ 135 
Figure 4.20 Annona muricata methanolic extract induces apoptosis in FTC-
133 cells .............................................................................................. 137 
Figure 4.21 Statistical analysis of apoptosis induction by A. muricata 
methanolic extract in FTC-133 cells. ................................................. 138 
Figure 4.22 Effect of A. muricata methanolic extract on DNA fragmentation in 
FTC-133 cells. .................................................................................... 140 
Figure 4.23 Relative mRNA expression of apoptosis-related genes (BCL2, 
BAX, CASP3 and MYC) in FTC-133 cells treated with A. muricata 
methanolic extract. Annona muricata methanolic extract induces 
apoptosis in FTC-133 cells. ................................................................ 142 
Figure 4.24 The relative microRNA expression level of (a) miR-192, (b) miR-
197, (c) miR-328 and (d) miR-346 in different thyroid cell origins 
measured by qPCR. ............................................................................ 144 
Figure 4.25 The microRNA expression level of (a) miR-192, (b) miR-197, (c) 
miR-328 and (d) miR-346 in FTC-133 cells treated with A. 
muricata methanolic extract measured by qPCR. .............................. 146 
Figure 4.26 The mRNA expression levels of (a) DYRK3 and (b) EREG, 
putative target genes of miR-192 in FTC-133 cells treated with A. 
muricata methanolic extract at 100 µg/mL for 24 hours measured 
by qPCR.. ........................................................................................... 149 
Figure 4.27 The mRNA expression levels of (a) SERTAD4, (b) PTPN9 and (c) 
ACVR1, putative target genes of miR-197 in FTC-133 cells treated 
 
xvi 
with A. muricata methanolic extract at 100 µg/mL for 24 hours 
measured by qPCR. ............................................................................ 151 
Figure 4.28 The mRNA expression levels of (a) FERMT2 and (b) DCAF7, 
putative target genes of miR-328 in FTC-133 cells treated with A. 
muricata methanolic extract at 100 µg/mL for 24 hours measured 
by qPCR. ............................................................................................ 152 
Figure 4.29 The mRNA expression levels of (a) NXPH1, (b) EFEMP2 and (c) 
ZNF12, putative target genes of miR-346 in FTC-133 cells treated 
with A. muricata methanolic extract at 100 µg/mL for 24 hours 




LIST OF EQUATIONS 
Page 
Equation 3.1 Calculation for total phenolic content. ................................................. 62 
Equation 3.2 Calculation for total flavonoid content. ................................................ 65 
Equation 3.3 Calculation for percentage of free radical scavenging activity. ........... 68 
Equation.3.4 Estimation for the number of cells per mL. .......................................... 73 
Equation 3.5 Calculation for percentage of cell viability using Trypan blue 
assay. .................................................................................................... 74 
Equation 3.6 Calculation for cell doubling time. ....................................................... 76 
 
xviii 
LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS 
 
ANOVA Analysis of variance 
AO  Acridine orange 
ATC Anaplastic thyroid carcinoma 
ATP Adenosine triphosphate 
BD Becton Dickinson 
bp Base pair 
cDNA Complementary deoxyribonucleic acid 
CO2 Carbon dioxide 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphates 
DPPH 2,2-diphenyl-1-picrylhydrazyl 
DTT Dithiothreitol 
dsRNA Double-stranded RNA 
dw Dry weight 
EB Ethidium bromide 
EDTA Ethylene diamine tetra acetic acid 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FITC Fluorescein isothiocyanate 
FTC Follicular thyroid carcinoma 
GAE Gallic acid equivalent 
 
xix 
H2O2 hydrogen peroxide 
IC50 Half maximal inhibitory concentration 
IDT Integrated DNA Technologies, Inc. 
MAPK  mitogen-activated protein kinase 
mg Miligram 
mL Mililiter 
mRNA Messenger ribonucleic acid 
MTC Medullary thyroid carcinoma 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium   
 bromide] 
NCI National Cancer Institute 
nm nanometer 
O2
− Superoxide ion 
O2 Oxygen 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PES Polyethersulfone 
pH Potential of hydrogen 
PI Propidium iodide 
PTC Papillary thyroid carcinoma 
PTEN Phosphatase and tensin homolog protein 
QE Quercetin equivalent 
RNA Ribonucleic acid 
rpm Revolutions per minute 
RPMI Roswell Park Memorial Institute 
 
xx 
RT-PCR Reverse transcriptase polymerase chain reaction 
SD Standard deviation 
SEM Standard error of the mean 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
UV Ultraviolet 
WHO World Health Organization 
w/v Weight/volume 












AKTIVITI ANTI-OKSIDA DAN ANTI-PROLIFERATIF PADA ENAM 
TUMBUHAN PERUBATAN DI MALAYSIA DAN MEKANISMA 




 Kanser tiroid, termasuk papilari, folikular, medulari dan anaplastik, 
mempunyai kadar pertumbuhan berbeza dan boleh merebak jika tidak dirawat. 
Walaupun kebanyakan kes kanser tiroid mempunyai prognosis yang baik, risiko 
perulangan di kalangan pesakit adalah tinggi dan pesakit mati akibat ketumbuhan 
tumor yang progresif. Tumbuhan ubat-ubatan biasanya digunakan sebagai alternatif 
kepada rawatan kanser di banyak negara. Aktiviti anti-proliferatif oleh fitokimia telah 
dilaporkan dalam pelbagai jenis kanser, namun kesan tumbuhan ubat-ubatan pada 
kanser tiroid masih kurang diselidiki. Walaupun terdapat pelbagai laporan tentang 
aktiviti anti-kanser ekstrak tumbuhan pada pelbagai sel kanser, sasaran selular dan 
mekanisme yang terlibat masih tidak jelas. Matlamat keseluruhan kajian ini adalah 
untuk mengkaji kesan ekstrak daripada enam tumbuhan perubatan (Annona muricata 
L., Angelica keiskei Ito, Chromolaena odorata (L.) R.M.King & H. Rob, Clinacanthus 
nutans (Burm. f.) Lindau, Euphorbia hirta L., and Leea indica (Burm. f.) Merr.) pada 
sel-sel tiroid (Nthy-ori 3-1, FTC-133 dan Hth-74) dan mekanisme yang terlibat. Untuk 
aktiviti anti-oksida dan anti-proliferatif, kaedah Folin-Ciocalteu, klorida aluminium, 
penghapusan DPPH radikal bebas dan MTT digunakan. Penilaian terhadap induksi 
apoptosis melalui pemberhentian kitaran sel menggunakan analisis sitometrik aliran 
sel yang dirawat dengan propidium iodide dan  Annexin V-FITC/propidium iodide, dan 
kaedah TUNEL, mengesahkan aktiviti anti-proliferatif dalam ekstrak tumbuhan. 
 
xxii 
Kaedah RT-PCR kuantitatif masa nyata bagi gen yang berkaitan dengan apoptosis, 
pada microRNAs dan gen target mereka juga dilakukan. Ekstrak metanol E. hirta 
mempunyai jumlah kandungan fenol dan flavonoid yang tinggi pada 307.59 ± 3.57 mg 
GAE/g dw dan 76.43 ± 4.34 mg QE/g dw. Ekstrak tersebut mempunyai 32% 
penghapusan DPPH dengan nilai IC50 0.013 mg/mL. Pengurangan ketara pada 
ketumbuhan sel dilihat pada ekstrak metanol A. muricata dan C. odorata dengan nilai 
IC50 20.8 dan 74.9 mg/mL dalam sel FTC-133 selepas 72 jam. Sel FTC-133 yang 
dirawat dengan ekstrak metanol A. muricata menunjukkan peningkatan ketara dalam 
peratusan sel pada fasa S- dan G2/M dengan penurunan yang ketara dalam fasa G0/G1. 
Analisa sitometrik aliran sel yang dirawat dengan Annexin V-FITC/propidium iodide 
dan analisis kajian TUNEL mengesahkan bahawa estrak metanol A. muricata 
menyebabkan apoptosis dalam sel FTC-133. Analisa ekspresi gen-gen berkaitan 
dengan apoptosis menunjukkan bahawa penghapusan sel secara intrinsik disebabkan 
oleh peningkatan ketara dalam ekspresi gen pro-apoptosis, BAX dan penurunan ketara 
dalam ekspresi gen anti-apoptosis, BCL2. Di samping itu, pengurangan ketara pada 
ekspresi beberapa microRNAs (miR-192, miR- 197, miR-328 dan miR-346) dalam 
FTC-133 sel yang dirawat dengan ekstrak metanol A. muricata mencadangkan aktiviti 
anti-proliferatif yang berasaskan mekanisma modulasi microRNA. Kesimpulannya, 
jumlah kandungan fenolik dan flavonoid yang banyak menyumbang kepada aktiviti 
anti-oksida yang tinggi. Ekstrak metanol A. muricata menghasilkan aktiviti anti-
proliferatif yang signifikan pada sel FTC-133 melalui kerencatan kitaran sel dan 
induksi apoptosis secara intrinsik. Kesan anti-proliferatif mungkin disebabkan oleh 
modulasi beberapa microRNA yang diekspres secara berlainan di dalam sel FTC-133. 
Potensi ekstrak metanol A. muricata dalam pencegahan perkembangan kanser tiroid 
bertumpu pada ekspresi microRNA harus diselidiki secara lebih lanjut.
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ANTIOXIDANT AND ANTIPROLIFERATIVE ACTIVITIES OF SIX 
MALAYSIAN MEDICINAL PLANTS AND MECHANISM OF ACTION 




Thyroid cancers, including papillary, follicular, medullary and anaplastic 
carcinomas, have different growth rates and can metastasize if left untreated. Even 
though most thyroid cancer cases have good prognosis, the risk of recurrence among 
the patients is high and some patients die from progressive tumor. Medicinal plants are 
commonly used as alternative to cancer treatment in many countries. The anti-
proliferative activity of phytochemicals has been demonstrated in various cancers, yet 
the effect of medicinal plants on thyroid cancer remain under-investigated. Despite 
various reports on the anti-cancer activities of plant extracts on a variety of cancer cell 
lines, the cellular targets and the underlying mechanisms remain unclear. The overall 
goal of the present study was to investigate the effect of crude extracts from six 
medicinal plants (Annona muricata L., Angelica keiskei Ito, Chromolaena odorata (L.) 
R.M.King & H. Rob, Clinacanthus nutans (Burm. f.) Lindau, Euphorbia hirta L., and 
Leea indica (Burm. f.) Merr.) on thyroid cell lines (Nthy-ori 3-1, FTC-133 and Hth-
74) and the mechanism involved. For antioxidant and anti-proliferative activities of 
the plant extracts, methods such as Folin-Ciocalteu’s, aluminum chloride, DPPH free 
radical scavenging assays and MTT assay were utilized. Flow cytometric analysis of 
treated cells stained with propidium iodide and with Annexin V-FITC/propidium 
iodide, and TUNEL assay further confirmed the anti-proliferative activity of the plant 
extract. Quantitative real-time RT-PCR of apoptotic related genes, candidate 
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microRNAs and their putative target genes were also performed. Methanolic extract 
of E. hirta had high amount of total phenolic and flavonoid contents at 307.59 ± 3.57 
mg GAE/g dw and 76.43 ± 4.34 mg QE/g dw, respectively. The extract had 32% of 
DPPH scavenging with IC50 of 0.013 mg/mL. Significant reduction of cell viability 
was observed when treated with A. muricata and C. odorata methanolic extracts with 
IC50 of 20.8 and 74.9 mg/mL in FTC-133 cells at 72 hours of treatment. FTC-133 cells 
treated with A. muricata methanolic extract showed significant increase in percentage 
of cells at the S- and G2/M-phase with subsequent significant decrease in G0/G1-phase. 
Flow cytometric analysis of cells treated with Annexin V-FITC/propidium iodide and 
analysis of TUNEL assay further confirmed that A. muricata methanolic extract 
induced apoptosis in FTC-133 cells. Gene expression analysis of apoptosis-related 
genes suggest that intrinsic apoptosis pathway was induced by the significant increase 
in expression of pro-apoptotic gene, BAX and significant decrease in expression of 
anti-apoptotic gene, BCL2. In addition, significant reduction in the expression of 
several microRNAs (miR-192, miR-197, miR-328 and miR-346) in FTC-133 cells 
treated with A. muricata methanolic extract suggest for potential underlying 
mechanism of the anti-proliferative property. In conclusion, large amount of phenolic 
and flavonoid compounds in E. hirta contributed to its high antioxidant activity. 
Treatment of A. muricata methanolic extract resulted in significant anti-proliferative 
activity in FTC-133 cells through cell cycle arrest and induction of apoptosis. The anti-
proliferative activity may also be due to modulation of several microRNAs aberrantly 
expressed in FTC-133 cells. The potential of A. muricata methanolic extract in the 
prevention of thyroid cancer development focusing on the microRNAs regulation 
pathway should be further investigated.  
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1.1 Rationale of the study 
With the increasing number of cancer incidence especially in developing countries, the 
cancer burden will likely be exasperated by the increase in growth, life expectancy, 
and aging of the population (Thun et al., 2009). Despite considerable effort and 
successes in managing cancer, it remains as one of the leading causes of death 
worldwide. About 7.6 million cancer deaths and 12.7 million cancer cases have 
occurred in 2008 worldwide and more than 50% of the cancer cases and deaths 
occurred in developing countries (Ferlay et al., 2010). It is projected that 26 million 
cases and 17 million deaths due to cancer will occur by 2030 (Thun et al., 2009).  
 
Thyroid cancer is a disease that forms in the thyroid gland, located on the front 
of the neck below the thyroid cartilage. Thyroid cancers can be classified based on the 
histopathological characteristics including papillary, follicular, medullary and 
anaplastic thyroid cancers. Each cancer groups have different growth rates and can 
metastasized if left untreated. In certain types of thyroid cancers, the malignancies are 
higher in women than in men with the ratio of 3:1. In 2012, about 230,000 new cases 
of thyroid cancer were diagnosed in women and 70,000 in men (Ferlay et al., 2015). 
The incidence rates are increasing over the last few decades in most countries and if 
the trends remain, thyroid cancer could be in the top four of the most common cancer 
by 2030 in the United States (Rahib et al., 2014). However, the mortality rates have 
been steadily declining in most part of the world, which are likely due to the improved 
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strategies for the diagnosis, management and treatment of the disease (La Vecchia et 
al., 2015).  
 
According to the Malaysian National Cancer Registry, between 2007 – 2011, 
thyroid cancer incidence was the highest among Malays for a total of 1335 cases 
(Azizah et al., 2016). In 2006, International Atomic Energy Agency reported that in 
Singapore, Malays have a higher incidence rate of thyroid cancer (males = 2.7, females 
= 5.0) than Chinese (males = 1.5, females = 4.3) and Indian population (males = 0.7, 
females = 1.1) per 100,000 population suggesting for possible genetic susceptibility in 
the Malays and predominantly in females. Nonetheless, thyroid cancer can occur in all 
age groups where in older patients, the cancer is significantly more aggressive.  
 
In thyroid cancer, tumors can recur in 30% of survivors and may develop 
chemo-resistance to currently available drugs (Palme et al., 2004; Tuttle et al., 2010). 
The causes for thyroid cancer recurrence remain to be investigated especially at the 
molecular level that lead to tumor recurrence. On the other hand, the inadequacy of 
current chemotherapeutic agents requires the development of new, effective and 
affordable anti-cancer drugs. The improvements in diet richer in vegetables and 
flavonoids over the last few decades may have contributed to the widespread decline 
in the mortality of thyroid cancer (Dal Maso et al., 2009). In addition, several studies 
have identified a panel of mutations specific to thyroid cancer types and with deeper 
understanding of the genetic and epigenetic alterations, patients may benefit from 
personalized therapeutic approaches. Indeed, development of targeted drugs to 
specifically modulate molecules related to cancer is the basis for precision medicine. 
Phytochemicals and herbal medicine act synergistically where they attack multiple 
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targets at the same time in which could be great resources for the use in targeted 
therapies. Therefore, development of novel anti-cancer drugs based on natural 
products for thyroid cancers will be of immense use in planning personalized treatment 
modalities.  
 
Natural products can be a major source for development of novel drugs. With 
more than 391 000 species in the plant kingdom, plants provide massive number of 
compounds with numerous chemical diversity with various pharmacological 
properties. When combined with high-throughput screens and the lead compounds can 
be optimized by combinatorial chemistry for potential drug development. The 
enormous diversity of plant species and the prevalence of traditional medicine practice 
in Malaysia provide a good platform of candidate species to be evaluated for anti-
cancer drug property.  
 
Many Malaysian plants are being used in traditional medicine to treat a myriad 
of diseases. Some have been suggested to be effective in treating cancer or preventing 
cancer recurrence, nonetheless, limited scientific evidence are available to support the 
local claims. Therefore, it is crucial to properly evaluate the anti-cancer properties of 
these plants in vitro, to understand the molecular basis and mechanism involve in the 
anti-cancer effect of the plant extracts in thyroid cancer including their involvement in 
apoptotic pathway and modulations of aberrantly expressed microRNAs. 
 
1.2 Aim and scope of the study 
Thus, the present study aimed to determine the antioxidant and anti-proliferative 
properties of six Malaysian medicinal plants – Angelica keiskei, Annona muricata, 
 
4 
Chromolaena odorata, Clinacanthus nutans, Euphorbia hirta and Leea indica in 
thyroid cell lines (Nthy-ori 3-1, FTC-133 and Hth-74) and the mechanism involved 
via regulation of microrna expression. The specific objectives include: 
I. To evaluate the total phenolic and flavonoid contents, and free radical scavenging 
activity of the aqueous and methanolic extracts of A. keiskei, A. muricata, C. 
odorata, C. nutans, E. hirta and L. indica using Folin Ciocalteu’s, aluminum 
chloride, and DPPH scavenging assay. 
II. To assess the anti-proliferative activity of the aqueous and methanolic extracts 
and their inhibitory concentrations at 50% in thyroid cell lines (Nthy-ori 3-1, 
FTC-133 and Hth-74) using MTT cell proliferation assay. 
III. To determine the association of anti-proliferative activity of candidate extract 
with cell cycle arrest using flow cytometric analysis. 
IV. To investigate the efficacy of a candidate extract in inducing apoptosis in thyroid 
cancer cells using flow cytometric analysis of Annexin V-FITC/propidium iodide 
stained cells and TUNEL assay and quantitative real-time RT-PCR of apoptotic 
genes.  
V. To investigate the potential involvement of microRNAs as an underlying 
mechanism of the anti-proliferative effect of candidate extract in thyroid cell line 
by quantifying the expression of associated microRNAs and their target mRNAs 
using quantitative real-time RT-PCR. 
 
1.3 Overview of the study 
Several steps were involved in completing the study. The first part of the study 
required preparation of the extracts and optimization of the assays involved in 
evaluating the antioxidant activity in the plant extracts. The second part involved the 
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preparation of the cells involved for the current study and evaluation of the growth 
condition and requirements specific to the cells. The last part of the study is the 
evaluation of the effect of the plant extracts on the thyroid cell lines in terms of anti-
proliferative activity, establishment of apoptosis in treated cells as well as the 
involvement of microRNAs in the anti-proliferative activity of the candidate extract. 




Figure 1.1 Flow chart of the study. Overview of the study design and analyses performed to determine the antioxidant and anti-proliferative 
activities of plant extracts in thyroid cell lines.
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Cancer happens when abnormal cells grow uncontrollably forming tumor mass and 
gain the ability to invade other tissues or other part of the bodies through the blood and 
lymph systems. With 8.8 million of deaths recorded in 2015, cancer is one of the 
leading causes of death globally (World Health Organization, WHO). Breast cancer, 
lung and bronchus cancer, prostate cancer and thyroid cancer are several of the cancers 
projected to be the most common cancers in 2018 (National Cancer Institute, NCI). 
Based on the data collected from GLOBOCAN 2012, the number of new cancer cases 
is estimated at 454.8 per 100,000 population per year and the number of cancer deaths 
is 171.2 per 100,000 population per year (WHO). Cancer pose a major threat to public 
health especially in developing nations where they have inadequate resources to deal 
with complex and expensive treatments for cancer. According to WHO, approximately 
70% of cancer deaths occur in low- and middle-income countries possibly due to 
diagnosis of disease at a later stage and inaccessibility or unavailability of diagnosis 
and treatment. In 2015, only 35% of low-income countries reported to have pathology 
services provided in the public sector (WHO).  
 
Cancer causes economic, emotional and social impacts to both the patient and 
the society. The financial costs of cancer are high for the patient and the society where 
an estimated medical cost for cancer in the United States in 2014 was $87.7 billion 
(The Agency for Healthcare research and Quality, AHRQ). In addition, cancer 
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treatment often affects the patient’s appearance leading to feeling of self-conscious 
and low self-esteem.  This also could lead to clinical depression where the American 
Cancer Society estimates up to one in four people with cancer develop depression 
during or after treatment. For some cancer survivors, re-entering social and 
professional life can be challenging affecting patients’ quality of life and work 
performance. 
 
 Cancer is a non-communicable disease (NCD) which is not just a burden to the 
person, society and economy but it is a potential societal responsibility. In 2011, 
United Nations met to discuss NCDs which include cancer, diabetes, cardiovascular 
and lung diseases, and called for new global targets and action plan to address NCDs. 
There are four risk factors for NCDs including the tobacco use, alcohol consumption, 
unhealthy dietary practices and physical inactivity. Furthermore, limited access to 
essential healthcare also increases the risk of NCDs. Interventions such as prevention 
of tobacco use and alcohol consumption may address NCDs. Additionally, WHO 
Global action plan focuses on achieving an 80% availability of affordable basic 
technologies and essential medicines in low- and middle-income countries (WHO, 
2013).  
 
There are several categories for cancers with more than 200 diverse types of 
cancer. Commonly, cancers are categorized by the organ or type of cells of origin. For 
instance, colon cancer commonly arises in the colon and cancer originates from 
melanocytes of the skin is known as melanoma. These cancers are grouped into several 
categories including carcinoma (skin or epithelial tissues), sarcoma (connective or 
supportive tissues), leukemia (blood-forming tissues), lymphoma and myeloma 
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(immune system cells), and central nervous system cancers (brain and spinal cord 
tissues). 
 
2.1.1 Thyroid cancers 
Thyroid cancer is a cancer that forms in the thyroid gland, located on the front of the 
neck, below the thyroid cartilage (Figure 2.1 a). It is shaped like a butterfly with a right 
and a left lobe connected by isthmus (Figure 2.1 b). Thyroid cancers are divided into 
several groups based on the histopathological characteristics including papillary, 
follicular, medullary and anaplastic thyroid cancers (DeLellis et al., 2004). Thyroid 
carcinomas arise from two cell types present in the thyroid gland (Xing, 2013). 
Papillary, follicular and sometimes anaplastic carcinomas arise from follicular cells 
that make thyroid hormone that affects heart rate, body temperature, and energy level 
while medullary carcinoma arises from parafollicular C cells that produce calcitonin 







Figure 2.1 Thyroid Cancer. Labeled illustration showing the location of the (a) 
thyroid gland in a male figure (Colliver, 2014) and (b) tumor growth in the left lobe of 





Thyroid cancers arise in people of all ages, where its aggressiveness increases 
with age (Haymart, 2009). If thyroid cancers are left untreated, it can spread to other 
parts of the body. According to NCI, thyroid cancers represent approximately 1% of 
all malignancies, estimating 60,220 of new cases and 1,850 of deaths from thyroid 
cancer in the United States for 2013. A disturbingly steady increase in thyroid cancers 
worldwide has been observed (Jemal et al., 2011; Pellegriti et al., 2013). It is the fastest 
rising cancer in women (Durante et al., 2013). According to the Malaysian National 
Cancer Registry (NCR), thyroid cancer incidence rate was 2.2 for male and 6.8 for 
female cancer incidence per 100 000 population in 2006. Several possible factors may 
contribute to the increase in incidence rate of thyroid cancer including environmental 
factors (e.g. increased radiation exposures), better detection methods and other 
undiscovered factors (Davies and Welch, 2006; Nikiforov and Nikiforova, 2011). The 
development of thyroid cancer can be caused by exposure to ionizing radiation to the 
neck region at an early age. Radiation exposure significantly increases the risk for 
thyroid malignancies as seen in children exposed to radiation after the accident at the 
Chernobyl nuclear power plant and nuclear bombings in Hiroshima and Nagasaki 
during the World War II (Nikiforov and Nikiforova, 2011; Pellegriti et al., 2013). The 
alarming rise of thyroid cancer incidence is not just due to improvements in detecting 
thyroid cancer, other undiscovered factors may also contribute to the rise. It is 
suggested that obesity may increase the risk of developing thyroid cancer (Harari et 
al., 2012), as well as exposure to pollutants and hazardous chemicals. 
 
With the advent of technology, thyroid cancer can be diagnosed early and the 
treatments work well for some types of thyroid cancer. Papillary and follicular thyroid 
cancers are the most curable by complete removal of the lobe that harbors the cancer. 
 
12 
Nonetheless, the recurrence rate among the survivors is quite high with up to 30% 
where the cancer may come back, sometimes decades after the initial treatment with 
increased incurability, morbidity and mortality (Palme et al., 2004; Tuttle et al., 2010). 
Therefore, better treatment and prevention methods are needed to control the disease. 
With the use of effective treatment and preventive method, the mortality rate can be 
significantly reduced.  
 
The most common type of thyroid cancers are papillary thyroid cancer (PTC) 
accounting for ~80% of thyroid cancer cases (Nikiforov and Nikiforova, 2011). PTC 
is commonly diagnosed in patients between the ages of 30 and 50 with higher 
incidence rate in women. Follicular thyroid carcinoma (FTC) accounts for 10 to 15% 
of all thyroid cancers, are often diagnosed in patients above the age of 45 where its 
aggressiveness increases with age. Medullary thyroid carcinoma (MTC) makes up 
about 3 to 5% of all thyroid cancers where females and males are equally affected. The 
least common type of thyroid cancer is anaplastic thyroid carcinoma (ATC) that affects 
less than 5% of thyroid cancer patients. ATC is the most aggressive and invasive of all 
thyroid cancers and is usually diagnosed in patients older than 65 years. PTC and FTC 
have the highest survival rates while ATC is the least responsive to treatment.  Table 
















Cell type Follicular Follicular Follicular C cell 




























(Modified from Nikiforov and Nikiforova, 2011) 
 
2.2 Cancer biology 
The body is made up of cells that grow and divide to produce new cells, and eventually 
die when old or damage via programmed cell death, apoptosis. The cell cycle is a 
tightly controlled process that leads to cell division and duplication where the process 
detects and repairs genetic damage in the cells (Vermeulen et al., 2003). Chemical 
signals convey the information to cells whether to divide or stop dividing in response 
to growth requirements. However, sometimes this orderly process goes wrong which 
is a key factor in cancer. The genetic material can become damaged or changed leading 
to mutations affecting normal growth (Kastan and Bartek, 2004). These mutated cells 
escape the cellular regulation, defy death and continue multiplying forming mass of 
tissues called tumor. Tumor can either be benign (non-cancerous) or malignant 
(cancerous). Benign tumor rarely spread to other parts of the body because it lacks the 
invasive properties of a cancer, but it still poses negative health effects.  
 
Malignant tumor, however, can invade surrounding tissue. The cells can break 
from the origin (primary site) and enter the bloodstream or lymphatic system to other 
sites spreading the cancer in a process termed metastasis. The more widely the cancer 
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metastasizes, the more difficult for it to be treated or eradicated (Kumar, 2010). The 
formation of cancer, termed carcinogenesis, can be divided into three distinct phases: 
initiation, promotion and progression (Gescher et al., 1998). The initiation of cancer 
begins when normal cells are exposed to endogenous or exogenous deoxyribonucleic 
acid (DNA) damaging agents (Greenwald, 1992; Helleday et al., 2014). Endogenous 
factors are those that arise within the body, often at the molecular or cellular level 
including age, endogenous hormones, genetic heritage and race. Exogenous agents 
such as carcinogenic chemicals (e.g. asbestos, tobacco), ionizing radiation (e.g. X-
rays) and viruses (e.g. human papilloma virus) can cause cellular changes such as DNA 
alterations and gene mutations. The normal cells undergo transformation forming 
abnormal cells (initiated cells) that may proceed to promotion and progression process. 
The initiated cells acquire several biological characteristics to become malignant 
including loss of capacity for apoptosis, acquisition of self-sufficiency in growth 
signals, and acquisition to invade neighboring tissues. The promotion and progression 
process involve clonal expansion of the initiated cells (promotion) where the cellular 
damage inflicted in the initiation phase is propagated creating pre-neoplastic cells 
leading to formation of neoplastic cells forming malignant tumor (progression). Figure 






Figure 2.2 Multistage process of cancer development. Cancer involves formation 
of initiated cells from normal cells that have mutated due to carcinogen exposure. The 
initiated cells undergo clonal expansion into pre-neoplastic cells and progress to 
neoplastic cells after acquiring several traits making them malignant. The malignant 
cells may metastasize to other parts of the body via the blood stream or the lymph 
system. (Modified from Siddiqui et al., 2015).         
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2.3 Oxidative stress and cancer development 
In the last three decades, growing evidence have shown that oxidative stress plays a 
key role in human cancer development. An imbalance between production of free 
radicals and oxidants and their elimination by antioxidant enzymes lead to oxidative 
stress. Reactive oxygen species (ROS) including oxygen, and its reduction products 
superoxide, hydrogen peroxide and hydroxyl radical are examples of common free 
radicals. Oxidative stress emerges from two main sources, internal and external 
sources. The sources for internal oxidative stress normally are found in the 
peroxisomes and mitochondrial including enzymes such as cytochrome P450 complex, 
xanthine oxidase and nicotinamide adenine nucleotide (NADPH) oxidase complexes, 
which catalyze the formation of reactive free radicals (Sosa et al., 2013). Oxidative 
stress from external sources could be generated from irradiation (e.g. by UV light, X-
rays, gamma-rays), chemical compounds (e.g. alcohol, environmental pollutants), and 
exercise (Sosa et al., 2013; Valko et al., 2006).  
 
The body generates free radicals as by-products of cells using oxygen to 
generate energy (Pham-Huy et al., 2008). Oxygen is a very common oxidizing agent. 
Oxygen-free radical is an atom or molecule with unpaired electrons that causes 
oxidative damage by stealing electrons from a surrounding compound or molecule 
(Winterbourn, 1993). At high concentrations, free radicals are capable of generating 
oxidative stress and damaging cells, leading to development of chronic and 
degenerative diseases including cardiovascular, neurodegenerative diseases and 
cancers (Bahoran et al., 2007; Halliwell, 2001; Valko et al., 2004). Cancer initiation 
and progression have been linked to oxidative stress by inducing DNA damage, 
introducing DNA mutations and genomic instability (Pelicano et al., 2004). 
 
17 
To protect cells from the negative effect of free radicals, antioxidant enzymes 
such as superoxide dismutase, glutathione peroxidase, and catalase reduce the free 
radicals by forming stable compounds (Thannickal and Fanburg 2000). For example, 
as shown in Figure 2.3, superoxide dismutase enzyme is responsible for 
disproportionation of superoxide (O2
−) to hydrogen peroxide (H2O2) and oxygen (O2) 
(McCord and Fridovich 1969). Then, the H2O2 is catalyzed into water (H2O) by 
catalase or glutathione peroxidase. Apart from endogenous antioxidants, other 
antioxidants can also be obtained from the diet including glutathione, β–carotene and 
ascorbic acid (vitamin C). Studies have shown that higher consumption of Vitamin C 
correlates with reduced risk for pancreatic, cervical and colorectal cancers (Block 
1991). Antioxidants are molecules that prevent inappropriate oxidation of other 
molecules where oxidizing agent steals electrons from another molecule forming free 
radicals (Lobo et al., 2010). It alleviates the effect of oxidative stress either by 
preventing ROS from being generated or by neutralizing them from the cell (Evans 








Figure 2.3 Role of superoxide dismutase in inactivation of the superoxide ion. 
Superoxide dismutase (SOD) catalyzes the dismutation of the superoxide ion (O2
−) into 
oxygen (O2) and hydrogen peroxide (H2O2). The hydrogen peroxide is then catalyzed 




2.4 Genetic mutations in cancer cells 
Cancer cells differ from normal cells in several characteristics including decreased 
drug sensitivity and increased invasiveness (Hartwell and Kastan, 1994). The acquired 
characteristics are from a process cellular evolution where multiple genetic changes 
have occurred. For an initiated cell to develop into neoplastic cells, six important 
hallmarks of cancers are necessary during its development (Hanahan and Weinberg, 
2011). The remarkable diversity of cancers is contributed by several cancer hallmarks 
including sustaining proliferative signaling, resisting cell death, evading growth 
suppressors, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis. 
 
 The most fundamental trait of cancer cells is to proliferate uncontrollably by 
sustaining proliferative signaling. In normal cells, in order to maintain the homeostasis 
of cell number, architecture and function, the production and release of growth-
promoting signals are tightly regulated (Hanahan and Weinberg, 2011). Nonetheless, 
cancer cells manage to deregulate these signals by producing growth factor ligands 
themselves thus stimulating endless growth (Sporn and Todaro, 1980), elevating levels 
of receptor proteins on the surface of cancer cells (Di Fiore et al., 1987), eliciting 
ligand-independent signaling (Su Huang et al., 1997) or by inducing adjacent normal 
cells to supply growth factors (Witsch et al., 2010). Somatic mutations in genes 
involved in MAPK (mitogen-activated protein kinase) cascades could also lead to 
cancer development where deregulated MAPK pathway is observed in one-third of 
human cancers (Dhillon et al., 2007). The MAPK pathway regulates cell proliferation 
regulated by external growth factors provided by surrounding cells. Additionally, 
cancer cells can also disrupt negative-feedback mechanisms involved in attenuating 
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proliferative signaling. For example, perturbations in PTEN (Phosphatase and Tensin 
homolog deleted from chromosome ten) signaling lead to cancer development. PTEN 
regulates PI3K (phosphatidylinositol 3-kinase) pathway by dephosphorylating the 
lipid signaling intermediate PIP3 (phosphatidylinositol (3,4,5)-triphosphate). Loss of 
PTEN function leads to increased level of PIP3 mimicking growth factor stimulation 
(Stambolic et al., 1998). Genetic investigations of thyroid tumors documented 
mutations in genes involved in the regulation of MAPK pathway commonly found in 
PTC and genes involved in the regulation of the PI3K pathway in FTC (Nikiforov, 
2011). Table 2.1 summarizes the genetic mutations commonly found in thyroid 
cancers.  
 
In addition to sustaining growth, cancer cells must also able to evade growth 
suppressors. The two most common tumor suppressors are p53 and pRb 
(retinoblastoma) proteins (Sherr and McCormick, 2002). Both proteins are involved in 
two main tumor suppressor pathways which control cellular responses to oncogenic 
stimuli. Mutations in these pathways can disrupt normal growth control or can 
dismantle cell cycle checkpoints. In thyroid cancer, mutations in TP53 which encodes 
p53 transcription factor, are associated with overexpression of the mutant form 
implicated in the aggressive subtypes of thyroid cancer (Ho et al., 1996).  The p53 
pathway is composed of a network of genes which respond to stress stimuli to control 
DNA replication, chromosome segregation and cell division (Vogelstein et al., 2000). 
The p53 role in promoting apoptosis was first studied by Yonish-Rouach et al., (1991) 




Resisting cell death is another hallmark of cancer development. Apoptosis, a 
programmed cell death mechanism has been established as the natural barrier of cancer 
development (Evan and Littlewood, 1998). Kerr et al., (1972) suggested that a large 
percentage of cell death from tumors is due to apoptosis. Spontaneously regressing 
tumors and tumors treated with anti-cancer agents display high frequency of apoptosis  
(Kerr et al., 1994). In addition to loss of p53 tumor suppressor function, cancer cells 
circumvent apoptosis through modulation of expression of the pro- and anti-apoptotic 
proteins. The apoptotic pathway is divided into two major pathways; the intrinsic and 
extrinsic pathways (Fulda and Debatin, 2006). Stimulation of both intrinsic and 
extrinsic pathways activates cysteine proteases called caspases (cysteine-aspartic 
proteases) prior to cell death. 
 
The intrinsic pathway involves p53-dependent pathway which is activated 
when signals within the cell initiate the process. The process is centered on the 
mitochondria where primary regulator proteins belonging to the Bcl-2 family activates 
the release of cytochrome c into the cytosol. The Bcl-2 family is consisted of anti- and 
pro-apoptotic proteins that interact with one another. The anti-apoptotic proteins 
include Bcl-2, Mcl-1 and Bcl-xL. On the other hand, Bax, Bak, Bad, Bid, Bik, Bim 
and Bcl-Xs are several of the pro-apoptotic proteins. After activation, Bax and Bak are 
recruited to the mitochondria and form pores (Antonsson et al., 1997) allowing for the 
cytochrome c to be released into the cytosol, forming apoptosome complex with Apaf-
1 (apoptotic protease-activating factor 1) (Liu et al., 1996; Zou et al., 1997). The 
apoptosome converts inactive pro-caspase 9 to active Caspase-9 (Hu et al., 1999). 
Then, Caspase-9 activates other caspases including Caspase-3 and Caspase-7 leading 
to apoptosis.  
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The extrinsic pathway is initiated upon ligation of death receptor including Fas 
or TNF (tumor necrosis factor) receptors by death signals from outside the cell 
(Krammer 2000, Siegel et al., 2000). Death signals bind to the death receptors on the 
surface of the cell converting inactive pro-caspase 8 into active Caspase-8. Caspase-8 
then activates caspase-3 initiating the caspase cascade leading to apoptosis. Figure 2.4 
gives a brief overview on the factors involved in the intrinsic and extrinsic apoptosis 
pathways. In addition to apoptosis, cancer cells may evade cell death by modulating 






Figure 2.4 Schematic representation of the intrinsic and extrinsic apoptosis 
pathways. The intrinsic pathway is typically initiated by DNA damage, which activates 
p53. The p53 then activates Bax initiating the release of cytochrome c from the 
mitochondria. The released cytochrome c binds to Apaf-1 forming a complex called 
apoptosome. The apoptosome converts inactive pro-caspase 9 to active Caspase-9, 
which then activates Caspase-3. Caspase-3 begins the caspase cascade leading to 
apoptosis. In the extrinsic pathway, death signals from outside of the cell bind to the 
death receptors on the surface of the cell converting inactive pro-caspase 8 into active 
Caspase-8. Caspase-8 then activates caspase-3, which begins the caspase cascade 
leading to apoptosis. (Modified from Favaloro et al., 2012). 
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  It is suggested that to form tumor mass, cancer cells require unlimited 
replication potential (Hanahan and Weinberg, 2011). Cancer cells must overcome the 
barriers for cell proliferation; replicative senescence and crisis. Senescence is a state 
of irreversible growth arrest that is triggered by multiple mechanisms including 
accumulation of DNA damage, epigenetic control of INK4a/ARF locus and telomere 
shortening (Collado et al., 2007). Abrogation of senescence leads to crisis, which 
involves cell death. Cells in crisis undergo spontaneous mitotic arrest leading to cell 
death. Cancer cells inhibit senescence and crisis through the upregulation of 
telomerase or by maintaining the telomere (Mathon and Lloyd, 2001). Additionally, 
inactivation of either p53 or pRb extends the lifespan of the cells despite short 
telomeres (Hara et al., 1991; Shay et al., 1991). 
 
The final hallmark of cancer is the ability to induce angiogenesis where cancer 
cells require sustenance to support the neoplastic growth (Hanahan and Folkman, 
1996). Angiogenesis is the formation of new blood vessels controlled by various 
signals including metabolic stress (e.g. low pH, hypoglycemia), inflammatory 
response and genetic mutations (Carmeliet and Jain, 2000). Without blood vessels, 
tumor is unable to grow or metastasize to other sites. Various proteins have been 
identified as angiogenic activators including angiogenin, VEGF (vascular endothelial 
growth factor), TGF-α (transforming growth factor α) and bFGF (basic fibroblast 
growth factor). Significant correlation has been shown between the VEGF expression 
and prognosis in several cancers including colorectal, breast, and lung cancers 
(Nishida et al., 2006). VEGF gene expression can be upregulated by hypoxia (i.e. 
reduced oxygen condition) and activation of oncogenes. Furthermore, experimental 
